Repatha FDA Approval History: Every Label Change From 2015 to Today

Repatha (evolocumab) is a PCSK9-targeting monoclonal antibody, not a statin and not a small-molecule drug. It belongs to the same drug class as Praluent (alirocumab) but is a distinct product with its own biologics license application. The FDA first approved it on August 27, 2015, for adults with familial hypercholesterolemia or established atherosclerotic disease who needed further LDL-C lowering beyond statin therapy. The FDA added a cardiovascular risk-reduction indication in December 2017 based on the FOURIER outcomes trial, and later extended coverage to pediatric HeFH and HoFH populations. As of 2026 the label carries no boxed warning. Because these three indications arrived years apart and have different eligibility criteria, a patient's specific diagnosis, not the drug's overall approval status, determines whether Repatha is actually indicated for them.

The useful question for most readers is not whether Repatha is FDA-approved, but which of its three indications applies to a given patient, the ASCVD risk-reduction indication, the HeFH indication, or the HoFH indication carry different age cutoffs, different supporting evidence, and different implications for expected benefit.

What the original 2015 approval covered

The FDA granted Repatha its initial approval on August 27, 2015, under BLA 125522, making evolocumab the first PCSK9 inhibitor to reach the U.S. market. The original label covered three populations: adults with HeFH, adults with HoFH, and adults with clinical ASCVD on maximally tolerated statin therapy who needed additional LDL-C reduction.

That approval rested on the phase 3 PROFICIO trial program, which enrolled several thousand patients across multiple studies, including the DESCARTES and RUTHERFORD-2 trials of LDL-C lowering in general hyperlipidemia and HeFH populations. At the time of the 2015 approval, the FDA was explicit that no cardiovascular-outcomes data existed. The original label stated that the effect of evolocumab on cardiovascular morbidity and mortality had not been determined, and Amgen committed to completing a large outcomes trial (FOURIER) as a post-marketing requirement.

Readers evaluating exact percentage LDL-C reductions from the original PROFICIO trials should check the primary publications directly; specific effect sizes from those studies are not repeated here because they could not be verified against a confirmed source during this revision.

Did the 2017 label change add real benefit, or just formalize what was already assumed?

The FOURIER trial changed Repatha's regulatory story. It was a large, randomized cardiovascular outcomes trial enrolling patients with established ASCVD and elevated LDL-C who were already on statin therapy, comparing evolocumab against placebo over a multi-year follow-up. The trial was published in the New England Journal of Medicine in 2017 and reported a reduction in the combined risk of major cardiovascular events (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) in the evolocumab arm.

In December 2017, the FDA approved a supplemental biologics license application adding a cardiovascular risk-reduction indication to the label, stating that Repatha is indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease. This is a meaningful distinction from the 2015 approval: the earlier label supported LDL-C lowering as a surrogate outcome, while the 2017 label change reflected direct trial evidence of reduced cardiovascular events, which is a materially stronger evidence basis under the standard hierarchy of trial evidence over surrogate-marker approval.

Exact hazard ratios and confidence intervals from FOURIER are widely cited in secondary sources, but this revision could not confirm a verified primary-source link for those figures during the drafting process. Readers who need precise numbers for clinical decision-making should pull them directly from the original NEJM publication or the FDA's approval documentation rather than relying on secondary summaries, including this one.

Does an FDA-approved indication mean it applies to your age group?

Repatha's pediatric and HoFH label history illustrates why "FDA-approved" is not a single fact but a set of separate approvals with separate age cutoffs.

For HeFH, the label was expanded to include patients age 10 and older, based on a pediatric randomized trial (commonly referenced as HAUSER-RCT) that reported LDL-C reduction in adolescents with a safety profile broadly similar to adults, including injection-site reactions as the most common adverse event. Published descriptions of that trial place its results around 2020; the exact date the pediatric HeFH label update took effect should be confirmed against FDA records before being stated as fact, since public summaries are not fully consistent on this point.

For HoFH, the label originally covered adults only and was later updated to include patients age 13 and older, informed by long-term open-label data (referenced as the TAUSSIG study) showing sustained but more modest LDL-C reductions than in HeFH or general ASCVD populations. This matters clinically: HoFH patients often have little or no functional LDL receptor activity, and PCSK9 inhibition works partly by upregulating LDL receptors. Patients with receptor-negative HoFH are expected to respond less robustly to evolocumab than patients with some residual receptor function, which is a real biological limit on transferring the drug's average trial effect to every HoFH patient.

Formulation and administration

Repatha is available in two delivery formats: a single-use prefilled autoinjector for the 140 mg dose and a single-use prefilled on-body infusor system for the 420 mg monthly dose, which delivers the larger volume over several minutes rather than requiring three separate injections. Standard cold-chain storage applies, as with most monoclonal antibody biologics: refrigerated storage is standard, with a limited allowance for room-temperature storage in the original carton before use. Patients should confirm current storage instructions on the dispensed product labeling rather than relying on a general description, since packaging and instructions can be updated.

What does the post-market safety record show, and is there a boxed warning?

Early in the approval process, the FDA and outside researchers raised a hypothesis-generating concern about neurocognitive effects at very low LDL-C levels, since cholesterol is a component of neuronal membranes. A prespecified cognitive substudy of FOURIER (commonly referenced as EBBINGHAUS) used standardized neuropsychological testing to compare evolocumab against placebo and reported no significant difference in cognitive function measures over extended follow-up, including among patients who achieved very low LDL-C. This is trial-level evidence addressing a specific safety hypothesis, not a guarantee that no individual patient can experience cognitive symptoms while on the drug.

The most commonly reported adverse events across the development program were injection-site reactions, along with respiratory infections occurring at rates broadly similar to placebo. Immunogenicity (development of antibodies against the drug) has been reported as uncommon. As of 2026, the current Repatha label does not carry a boxed warning. This status can change; readers should check the current FDA label directly at Drugs@FDA or the FDA's drug safety communications page for any postmarket safety updates issued after this article's publication date.

How does Repatha's label compare to other PCSK9-pathway drugs?

Repatha is not the only approved therapy targeting PCSK9. Praluent (alirocumab), a separate monoclonal antibody from a different manufacturer, was approved by the FDA in 2015 around the same period as Repatha and later received its own cardiovascular-outcomes indication based on a separate large outcomes trial (commonly referenced as ODYSSEY Outcomes). Inclisiran (Leqvio) is a different drug class entirely: a small interfering RNA (siRNA) therapy that reduces PCSK9 synthesis in the liver rather than blocking the circulating protein, dosed roughly twice yearly after an initial loading period. As of this writing, inclisiran's label is centered on LDL-C lowering, and its dedicated cardiovascular outcomes trial had not yet reported full results in the material available for this review; readers should check the current FDA label for inclisiran directly, since this can change.

Guideline bodies, including cardiology societies that publish cholesterol management guidance, generally recommend PCSK9-pathway therapies as add-on treatment for patients at very high ASCVD risk whose LDL-C remains above target despite maximally tolerated statin and ezetimibe therapy, without preferentially endorsing one specific PCSK9 inhibitor over another. Readers should consult the current guideline text directly for exact LDL-C thresholds, since these numbers are periodically revised.

Does FDA approval guarantee coverage, and has the price changed?

FDA approval and insurance coverage are not the same thing, and Repatha's history shows the gap clearly. At launch in 2015, the reported list price was in the range of roughly $14,000 per year, and payers responded with strict prior authorization criteria requiring documented statin intolerance or a failed ezetimibe trial. Amgen later reduced the list price substantially, with public reporting around 2018 describing a price cut of roughly 60%. These figures are carried from public reporting at the time and should be re-verified against current pricing before being used in any patient-facing cost discussion, since list prices, discounts, and out-of-pocket costs change over time and vary by plan.

Coverage patterns also shifted after the 2017 cardiovascular-outcomes label expansion, since payers generally weight trial-confirmed outcomes evidence more heavily than surrogate LDL-C lowering alone when setting prior authorization policy. A patient's actual out-of-pocket cost depends on their specific insurance plan, formulary tier, and any manufacturer assistance program currently in effect, none of which can be determined from a general regulatory history.

International approval status

Repatha has been authorized in multiple countries beyond the United States. The European Medicines Agency's public assessment materials are available directly at the EMA's Repatha EPAR page, which readers should consult for the current EU-approved indications and any label differences from the FDA version, since agencies do not always update indications on the same schedule. In general, when a drug's cardiovascular-outcomes claim is added in one major jurisdiction, other regulators reviewing the same outcomes trial tend to reach a similar conclusion within roughly a year, though exact timing and label wording differ by agency.

What the current label covers

As of 2026, the Repatha label includes three distinct indications: adults with established ASCVD (to reduce risk of MI, stroke, and coronary revascularization), pediatric and adult patients with HeFH from age 10 and up (as an adjunct to diet and maximally tolerated statin therapy), and patients with HoFH from age 13 and up (as an adjunct to diet and other LDL-lowering therapies). Dosing is 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly, with both regimens intended to achieve comparable LDL-C lowering at steady state. The labeled contraindication is a history of serious hypersensitivity reaction to evolocumab. This summary reflects publicly described label content; the authoritative source is the current FDA-approved prescribing information, which should be checked directly for the exact current wording, since labels are amended over time.

What is established, what is plausible, and what is not established

Established on the current label: an ASCVD risk-reduction indication supported by a completed cardiovascular outcomes trial, an HeFH indication with a pediatric extension down to age 10, an HoFH indication extended to age 13, a twice-monthly or monthly dosing option, and the absence of a boxed warning as of 2026.

Plausible but requiring primary-source confirmation before precise citation: the exact hazard ratios and percentage risk reductions from the FOURIER trial, the exact date the pediatric HeFH label update took effect, and current list-price and rebate figures, since none of these could be independently verified against a confirmed primary source during this revision.

Not established from the material reviewed here: any claim that evolocumab's cardiovascular benefit applies uniformly regardless of baseline LDL-C, statin use, or receptor status in HoFH; and any claim about long-term (beyond the trial follow-up windows) cardiovascular or cognitive safety, since post-market surveillance continues and long-term data accumulate over time.

A decision framework for reading a Repatha label change

Because Repatha's approval history is really three separate approvals stitched together, the practical question for a patient or clinician is which part of the history actually applies to them. Use this to sort a specific situation rather than treating "Repatha is FDA-approved" as a single fact.

When to seek care urgently rather than wait for a label question to be answered

A question about which FDA indication applies to a patient is not an emergency. Symptoms that warrant urgent evaluation regardless of any label detail include signs of a serious allergic reaction after an injection (facial or throat swelling, difficulty breathing, widespread hives), chest pain, sudden weakness or slurred speech, or any acute symptom consistent with a heart attack or stroke. Label history and approval dates are background for a conversation with a prescriber, not something to research in place of seeking care for acute symptoms.